Bristol-Myers Squibb Company
NYSE:BMYDrug Manufacturers - General
-$1.42 today
- Market cap
- $121.75B
- Beta
- 0.24
- P/E (TTM)
- 15.1
- EPS (TTM)
- $3.56
- Dividend yield
- 4.64%
Volume 9.54M
Average 11.50M
BMY EBITDA Margin
EBITDA as a percentage of revenue.
Bristol-Myers Squibb CompanyNYSE: BMY
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 39.2%
EBITDA Margin was 39.2% in Q2 FY2026, up 12.6 pp from a year earlier. On a trailing-twelve-month basis it was 34.2%, up 2.6 pp year over year. Over 3 fiscal years it narrowed by 10.0 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 19 analysts of 40.2% for the fiscal year ending Dec 2026, up from 31.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 39.2%+2.3 pp QoQ
- Last fiscal yearDec 2025
- 31.6%+25.0 pp YoY
- LTMJun 2026
- 34.2%+2.6 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +12.6 pp | -9.8 pp | -22.3 pp |
| 1 year | +25.0 pp | +8.6 pp | -16.4 pp |
| 3 years | -10.0 pp | +9.7 pp | +19.7 pp |
| 5 years | +9.2 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 31.6%
- Year-over-year change
- +25.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.6% | +25.0pp |
| FY2024 | 2024-12-31 | 6.6% | -36.5pp |
| FY2023 | 2023-12-31 | 43.0% | +1.4pp |
| FY2022 | 2022-12-31 | 41.6% | -1.7pp |
| FY2021 | 2021-12-31 | 43.4% | — |
EBITDA Margin vs competitors
How BMY compares with its peers on the latest reported figures
- BMY's LTM Jun 2026 EBITDA Margin of 34.2% is the 6th highest of the 11 companies compared; the peer median is 32.7%.
- Its year-over-year change of +2.6 pp is the 4th highest of 11, against a peer median of -0.9 pp.
- Over three fiscal years its change of -10.0 pp compares with a peer median of +7.9 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 54.4% | +14.4 pp | +18.3 pp | |
| LTM Jun 2026 | 46.2% | +0.7 pp | -0.2 pp | |
| LTM Jun 2026 | 40.0% | -1.1 pp | +8.2 pp | |
| LTM Sep 2026 | 36.6% | +15.1 pp | -12.8 pp | |
| LTM Sep 2026 | 34.4% | +3.4 pp | +13.3 pp | |
| LTM Jun 2026 | 34.2% | +2.6 pp | -10.0 pp | |
| LTM Sep 2026 | 31.0% | -11.9 pp | +10.3 pp | |
| LTM Jun 2026 | 26.5% | -0.7 pp | +2.5 pp | |
| LTM Jun 2026 | 21.2% | -10.4 pp | -13.7 pp | |
| LTM Jun 2026 | 21.0% | -18.3 pp | +7.6 pp | |
| LTM Jun 2026 | 4.4% | -33.6 pp | +13.7 pp | |
| Peer median (excluding BMY) | 32.7% | -0.9 pp | +7.9 pp | |
Competitors are the stored peer set for BMY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 46.39B | 46.16B | 45.01B | 48.3B | 48.2B |
| Cost of Revenue | 9.94B | 10.14B | 10.69B | 13.97B | 13.94B |
| Gross Profit | 36.45B | 36.02B | 34.31B | 34.33B | 34.26B |
| Gross Margin | 78.6% | 78.0% | 76.2% | 71.1% | 71.1% |
| Research & Development | 10.2B | 9.51B | 9.3B | 11.16B | 9.95B |
| Selling, General & Admin | 7.69B | 7.81B | 7.77B | 8.41B | 7.27B |
| Operating Expenses | 27.91B | 26.92B | 26.12B | 28.45B | 20.54B |
| Depreciation & Amortization | 10.69B | 10.28B | 9.76B | 9.6B | 4.01B |
| EBITDA | 20.12B | 19.22B | 19.37B | 3.17B | 15.23B |
| EBITDA Margin | 43.4% | 41.6% | 43.0% | 6.6% | 31.6% |
| Operating Income | 8.54B | 9.1B | 8.2B | 5.89B | 13.72B |
| Operating Margin | 18.4% | 19.7% | 18.2% | 12.2% | 28.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.33B | 1.23B | 1.17B | 1.95B | 1.89B |
| Other Income / Expenses | (439M) | (1.39B) | 245M | (14.27B) | (4.4B) |
| Income Before Tax | 8.1B | 7.71B | 8.44B | (8.38B) | 9.33B |
| Pre-Tax Margin | 17.5% | 16.7% | 18.8% | -17.3% | 19.4% |
| Income Tax Expense | 1.08B | 1.37B | 400M | 554M | 2.27B |
| Net Income | 6.99B | 6.33B | 8.03B | (8.95B) | 7.05B |
| Net Margin | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% |
| EPS (Basic) | 3.15 | 2.97 | 3.88 | (4.41) | 3.46 |
| EPS (Diluted) | 3.12 | 2.95 | 3.86 | (4.41) | 3.45 |
| Weighted Avg Shares | 2.22B | 2.13B | 2.07B | 2.03B | 2.04B |
| Weighted Avg Shares (Diluted) | 2.25B | 2.15B | 2.08B | 2.03B | 2.04B |
Bristol-Myers Squibb Company
NYSE:BMY
Intrinsic Alpha fair value
Locked
Current Price
$59.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.